Literature DB >> 34977322

Estimating the global prevalence of hepatitis E virus in swine and pork products.

Pengfei Li1, Yunpeng Ji1,2, Yunlong Li1, Zhongren Ma2, Qiuwei Pan1,2.   

Abstract

Zoonotic transmission of hepatitis E virus (HEV), in particular the genotype (GT) 3 and GT4 strains, constitutes a major one health issue. Swine serves as an important reservoir and the processed pork products essentially contribute to foodborne transmission. This study comprehensively estimated HEV prevalence in domestic pigs, wild boars, and pork products. At global level, we found nearly 60% domestic pigs and 27% wild boars have ever encountered HEV infection based seroprevalence rate. Nearly 13% domestic and 9.5% wild swine are actively infected based on HEV RNA positivity. Importantly, about 10% of commercial pork products are HEV RNA positive, although available data are limited in this respect. Our results indicate the high prevalence rate of HEV infection in pigs and widespread contamination in pork products, although there are substantial variations at regional and country levels. These findings are important for better understanding the global epidemiology and clinical burden of HEV infection in human population related to zoonotic transmission.
© 2021 Published by Elsevier B.V.

Entities:  

Keywords:  95% CI, 95% confidential interval; GT, Genotype; HEV, hepatitis E virus; Hepatitis E virus; Pork products; Prevalence; Swine; Zoonotic transmission

Year:  2021        PMID: 34977322      PMCID: PMC8686068          DOI: 10.1016/j.onehlt.2021.100362

Source DB:  PubMed          Journal:  One Health        ISSN: 2352-7714


Introduction

Hepatitis E virus (HEV) is a non-enveloped, single-stranded positive-sense RNA virus. It is recognized as the leading cause of acute viral hepatitis. Globally, it is estimated approximately 939 million corresponding to 1 in 8 individuals have ever been infected with HEV [1]. Among the different HEV genotypes (GT) that affect human health, GT3 and GT4 are zoonotic, which have been found in various animal species [2]. Although HEV infection is usually self-limiting or asymptomatic in healthy individuals, GT3 and GT4 HEV infection in organ transplant patients is prone to develop chronic hepatitis [3,4]. Pigs serve as the major reservoir for the zoonotic HEV strains. Anti-HEV antibodies have been widely detected in both domestic pigs and wild boars [[5], [6], [7]]. There are different routes of HEV transmission from pigs to humans, such as direct contact with the animal, indirectly through contaminated environment and the consumption of pork products. However, the contribution of these different transmission routes can vary tremendously among different settings attributing to multi-factors, such as socioeconomic status, farming systems, food chains and life styles. Nevertheless, the widespread consumption of pork products is inevitably posing a major risk of HEV foodborne transmission in public health. Hepatitis E cases linking to consuming undercooked pork or wild boar meat have been widely reported [8,9]. Globally, the epidemiological feature and clinical burden of HEV infection in human population are distinct among different countries/regions [1]. It is intriguing to postulate whether this is associated with the specific prevalence rate of HEV in local swine population and available pork products. In this study, we aim to estimate the global prevalence of HEV in both domestic pigs and wild boars, as well as pork products in retailers.

Methods

Data sources, search strategies and study selection

A systematic search was conducted in Medline, Embase, Web of science, Cochrane CENTRAL and Google scholar. Databases were searched for articles in English language from inception until 31 May 2021. Studies were included if they contained epidemiological data about HEV in domestic pig or wild boar. The full search strategies and study selection criteria are provided in the Supplementary file S1-S2.

Data extraction, quality assessment and statistical analysis

Eligible studies were further divided into three study populations: domestic swine, wild boars and market/retailer pork products. Studies were scored according to Joanna Briggs Institute checklist for prevalence studies [10]. A 95% confidence interval (95% CI) was estimated using Wilson score method, and pooled prevalence rate was calculated by the DerSimonian-Laird random-effects model with Freeman-Tukey double arcsine transformation. Funnel plots and Egger regression test were used to assess potential publication biases. ‘Meta’ package in the R-3.5.3 statistical software was used for meta-analysis as previously described [11,12]. Sensitivity analysis was performed by using ‘metainf’ to investigate the effects of group source and potentially unrepresentative samples. The details of quality assessment and statistical analysis are provided in supplementary S3.

Results and discussion

By comprehensively searching 5 databases (Supplementary S1–S3), we identified a total of 215 studies met the inclusion criteria, which were processed for analysis of HEV prevalence in domestic pigs, wild boars and pork products (sFig. 1). First, we estimated anti-HEV seroprevalence (indication of ever exposure) and HEV RNA positivity (indication of active infection) in domestic pigs. A total of 84 studies were included to estimate the global anti-HEV seroprevalence, resulting in a pooled rate of 59.33% (37 countries, 95% CI 53.64–64.90, I = 99%; sFig. 2). The highest seroprevalence was found in Oceania (75%, 95% CI 64.28–84.40), but this is only based on one study which likely causes bias in estimation. The second highest seroprevalence rate was found in Asia (67.45%, 95% CI 53.50–79.99, I = 100%), followed by Europe (57.46%, 95% CI 49.82–64.93, I = 99%), Africa (53.46%, 95% CI 43.26–63.52, I = 92%), and South America (53.03%, 95% CI 33.79–71.81, I = 99%) (sFig. 3). Based on 118 studies from 45 countries/territories, the global estimation of HEV RNA positive rate was 12.71% (95% CI 10.81–14.73, I = 97%). The highest rate was found in North America (18.10%, 95% CI 8.71–29.84, I = 97%), followed by Europe (17.19%, 95% CI 13.16–21.61, I = 98%), South America (15.67%, 95% CI 6.75–27.33, I = 98%), Africa (12.29%, 95% CI 0.01–38.70, I = 99%), Asia (8.23%, 95% CI 6.21–10.49, I = 97%), and Oceania (6.52%, 95% CI 2.23–12.63) (sFigs. 4 and 5). At country level, HEV prevalence in domestic pigs varies substantially, from 9.90% (Thailand, 95% CI 8.01–11.96) to 84.02% (India, 95% CI 44.05–100.00, I = 99%) of anti-HEV seroprevalence, and from 0% (Croatia, 95% CI 0.00–0.37) to 76.67% (Nigeria, 95% CI 67.32–84.89) of HEV RNA positivity (Table 1, Fig. 1). Importantly, we have collected genotyping information of swine HEV. GT3 is universally prevalent across the globe, whereas GT4 is mainly present in Western Pacific region. Interestingly, GT3 and GT4 are co-circulating in countries/territories, such as mainland China, Taiwan, Korea and Japan (Table 1, Fig. 1). This is consistent with clinical observations that both GT3 and GT4 HEV patients have been reported from these regions [[13], [14], [15], [16]]. Although Europe is dominated by GT3, GT4 HEV has been identified in some peculiar cases including chronically infected patients [17]. Here, we found that GT3 and GT4 are also co-circulating in domestic pig populations in Belgium (Fig. 1). Thus, the emergence of GT4, which is thought to be more pathogenic, requires more attention from both public health and patient care perspectives.
Table 1

HEV prevalence in domestic swine.

ContinentCountryAnti-HEV antibodies
HEV RNA
Genotype
No. of studiesEventsTested (n)Prevalence (%)95% CINo. of studiesEventsTested (n)Prevalence (%)95% CI
AsiaBangladesh18210082.0073.80–88.98
China13703615,46165.7346.01–82.9926123319,49310.407.48–13.74Major GT4; Minor GT3
India229736084.0244.05–100.004307463.350.71–7.57GT4
Indonesia222430772.9967.85–77.84233070.930.06–2.48GT4
Korea5162129411.134.63–19.85Major GT3; Minor GT4
Japan332744274.3339.02–97.424828693.010.00–13.24GT3 + GT4
Laos276989981.3626.33–100.002264555.690.01–18.78GT4
Philippines115529951.8446.16–57.491222997.364.65–10.62GT3
Vietnam130058651.1947.14–55.24114877419.1216.42–21.97GT3
Thailand1878799.908.01–11.961258752.861.85–4.07GT4
Taiwan28281610.170.00–43.06GT3 + GT4
Total26927719,33367.4553.50–79.9948181325,9288.236.21–10.49
EuropeBelgium130742073.1068.74–77.23181156.962.91–12.43GT3 + GT4
Bulgaria4652104961.6948.15–74.38
Croatia2524148464.948.05–100.00104690.000.00–0.37
CzechGT3
Denmark1489749.4839.53–59.45
Estonia123438061.5856.63–66.41110344922.9419.16–26.95GT3
Finland1156722.3913.11–33.23GT3
France31785781438.199.19–72.966343594915.607.61–25.66GT3
Germany31949386154.7954.92–77.30131202.500.31–6.24GT3
Greece1769679.1770.41–86.76
Hungary15224820.9716.11–26.27GT3
Ireland18933026.9722.31–31.90
Italy62961573766.5854.92–77.308311203119.209.68–30.95GT3
Lithuania116838443.7538.82–48.74110647022.5518.88–26.45
Netherlands277597675.2360.91–87.1825516138.901.20–88.42GT3
Norway148466373.0069.55–76.32
Poland16314344.0635.99–52.28151463.420.97–7.11
Portugal142913.793.21–29.132442297.940.00–40.29GT3
Romania161931.5812.27–54.50GT3
Serbia227165441.1428.63–54.2515133015.4511.74–19.57GT3
Slovenia214289615.7013.36–18.18GT3
Spain5651192549.6627.37–72.0256442711.774.72–21.23
Sweden215060325.4018.14–33.42GT3
Switzerland21281219958.2756.20–60.33
UK269280579.5642.36–99.545232148319.316.05–37.45GT3
Total3912,96628,94957.4649.82–64.9344176814,42217.1913.16–21.61
OceaniaNew Zealand1547275.0064.28–84.40
New Caledonia16926.522.23–12.63GT3
Total1547275.0064.28–84.4016926.522.23–12.63
North AmericaCanada159499859.5256.45–62.5523220022.700.00–80.63GT3
Costa Rica1195236.5423.90–50.16GT3
Mexico3964205544.9827.55–63.0722813010.400.00–56.02
USA22036511739.7338.39–41.083366525615.523.57–33.50GT3
Cuba1105318.879.32–30.65GT3
Total63594817045.0635.45–54.869455569118.108.71–29.84
South AmericaArgentina1229722.6814.84–31.5925918947.030.00–100.0GT3
Brazil51021154260.3837.62–81.01712316017.191.86–15.41GT3
Uruguay110322046.8240.25–53.4412515016.6711.09–23.09GT3
Colombia18725034.8029.01–40.83GT3
Total71146185953.0333.79–71.8111294234115.676.75–27.33
AfricaCameroon228661546.5042.56–50.46181365.882.45–10.56GT3
Madagascar117825071.2065.42–76.66133450.870.11–2.19GT3
Nigeria220440651.7641.76–61.701699076.6767.32–84.89GT3
Congo11402.500.00–10.42GT3
South Africa171604.381.66–8.18
Total5668127153.4643.26–63.5258877112.290.01–38.70
OverallGlobal8427,70559,65459.3353.64–64.90118442449,24512.7110.81–14.73GT3 + GT4
Fig. 1

Global prevalence of anti-HEV seroprevalence and HEV RNA positivity among domestic swine.

HEV prevalence in domestic swine. Global prevalence of anti-HEV seroprevalence and HEV RNA positivity among domestic swine. Next, we performed subgroup analysis of pigs at different developmental stages of their life. As expected, the anti-HEV seroprevalence rate increases over time, from 42.19% (95% CI 26.79–58.40, I = 97%) in 0–4 month old pigs, 49.27% (95% CI 30.37–68.29%, I = 98%) in 5–8 month pigs, to 66.20% (95% CI 55.78–75.89, I = 97%) in over 9 month age pigs. In contrast, the positive rate of HEV RNA showed a reverse pattern, with positive rate of 17.62% (95% CI 12.83–22.96, I = 91%) in pigs of 0–4 month age, 10.75% (95% CI 4.26–19.51, I = 89%) of 5–8 month age, and 6.59% (95% CI 0.86–16.27, I = 95%) over 9 month age (Fig. 2, sFigs. 6 and 7).
Fig. 2

Subgroup analysis of anti-HEV seroprevalence or HEV RNA positivity.

Subgroup analysis of anti-HEV seroprevalence or HEV RNA positivity. Considering the clear differences in husbandry and natural habitat between wild and domesticated pigs, we separately estimated HEV prevalence in wild boars. Based on data extracted from 33 studies from 19 countries/territories, we estimated that the overall anti-HEV seroprevalence was 26.82% (95% CI 21.69–32.28, I = 98%) (Table 2, sFig. 8). Based on 37 studies from 18 countries/territories, the pooled rate of HEV RNA positivity was 9.45% (95% CI 6.42–12.96, I = 96%) (Table 2, sFig. 9).
Table 2

HEV prevalence in wild boars.

CountryAnti-HEV antibodies
HEV RNA
Genotype
No. of studiesEventsTested (n)Prevalence (%)95% CINo. of studiesEventsTested (n)Prevalence (%)95% CI
China118675824.5221.51–27.67
Korea11041273638.0536.24–39.8812418591.290.82–1.86Major GT4, minor GT3
Japan6262113919.2610.13–30.3759326093.202.51–3.95Major GT3, minor GT4
Thailand11313.230.00–13.33GT3
Bulgaria19824040.8334.68–47.13
Croatia1311100031.1028.27–34.0111715011.336.70–16.95
Czech1313668.475.82–11.56
Estonia18147117.2013.92–20.751138116.058.77–24.93GT3
France216076721.078.35–37.622156372.351.28–3.71GT3
Germany18118045.0037.78–52.33415770122.333.34–51.18GT3
Hungary187510.674.53–18.80
Italy6560341633.5915.76–54.2110232169713.566.57–22.46GT3
Lithuania117831257.0551.51–62.5018650517.0313.87–20.44
Netherlands1293102928.4725.76–31.27281582.670.00–14.30
Poland19029031.0325.83–36.49
Portugal12412020.0013.28–27.67GT3
Romania195018.008.41–30.02GT3
Slovenia18728830.2125.03–35.65112880.350.00–1.49
Spain4409129941.5125.30–58.7224329614.476.48–24.86
Sweden1131598.184.36–13.00GT3
Switzerland13830312.549.03–16.52
Turkey109300.00–1.84
EU/multiples11210411.546.02–18.47141043.850.83–8.58
Uruguay13114022.1415.62–29.431131409.294.97–14.72
Total33394914,93126.8221.69–32.283776196609.456.42–12.96
HEV prevalence in wild boars. Given the important role of foodborne transmission, we collected data on HEV RNA detection rates of pork meat, liver and sausage in retailers. This generated pooled positive rate of 9.5% (95% CI 5.14–14.90, I = 94%), with 13.27% (95% CI 0.99–35.12, I = 98%) in meat, 6.59% (95% CI 1.83–13.49, I = 92%) in liver and 11.70% (95% CI 7.62–16.47, I = 71%) in sausage (sFig. 10). Sausage production represents a very large industry across the globe, particularly in Europe. Sausages are popular in groceries and sold in a variety of species [18]. We thus further compared the HEV positivity between liver sausage and pork sausage. Notably, we estimated a nearly 3-fold HEV positivity rate of 15.23% (95% CI 11.62–19.21, I = 0%) in liver sausage, compared with 5.54% (95% CI 0.19–15.20, I = 82%) in pork sausage (Fig. 2, sFigs. 11–12). Finally, we performed sensitivity analysis for HEV prevalence in domestic pigs and wild boars. In this meta-analysis, no significant change was observed by arbitrarily excluding any study from these groups. This low sensitivity supports the reliability of our estimation. However, funnel plot and Egger's test indicate the presence of publication bias (p > 0.05) in three analyses, including seroprevalence and HEV RNA prevalence among domestic swine, and RNA prevalence among wild boars, which may potentially compromise the accuracy of prevalence estimation (sFigs. 13–26). Another limitation of our study is that we were unable to estimate HEV prevalence in pork products at regional/country levels and clarify the original place of the products, due to limited data available. Because the current food production and supply chains are diverse and complicated; it has become increasingly important to trace the origin of the contaminated products. In summary, we found nearly 60% domestic pigs and 27% wild boars have ever encountered HEV infection at global level. Nearly 13% domestic and 9.5% wild swine are experiencing active infection. The risk of potential foodborne transmission is highlighted by our estimation that around 10% commercial pork products are HEV RNA positive. However, there remains gaps of translating these knowledge for better understanding the global epidemiology and clinical burden of HEV infection in human population related to zoonotic transmission. Because HEV zoonosis also involves many other factors, including socioeconomic status, farming style, food production and supply, as well as life styles. Nevertheless, our findings have set a stage for future research to further study the role of swine related HEV zoonosis and to facilitate the development of intervention and prevention strategies.

Author contributions

P. L., Z. M. and Q. P.: Project conceptualization. P. L., Y. L. and Y. J.: Data analysis. P. L. and Q. P.: Manuscript writing. Z. M. and Q. P.: supervised the project. All authors reviewed and approved the manuscript.

Ethical approval

The authors confirm that the ethical policies of the journal, as noted on the journal's author guidelines page, have been adhered to.

Data availability statement

All data needed to evaluate the conclusions in the paper are present in the paper and/or the Appendix.

Declaration of Competing Interest

The authors do not have any disclosures to report.
  16 in total

1.  The genetic divergences of codon usage shed new lights on transmission of hepatitis E virus from swine to human.

Authors:  Jian-Hua Zhou; Xue-Rui Li; Xi Lan; Sheng-Yi Han; Yi-Ning Wang; Yonghao Hu; Qiuwei Pan
Journal:  Infect Genet Evol       Date:  2018-12-02       Impact factor: 3.342

2.  Serological prevalence of hepatitis E virus in domestic animals and diversity of genotype 4 hepatitis E virus in China.

Authors:  Yansheng Geng; Chuanbin Wang; Chenyan Zhao; Xiuling Yu; Tim J Harrison; Kegong Tian; Youchun Wang
Journal:  Vector Borne Zoonotic Dis       Date:  2009-12-20       Impact factor: 2.133

3.  Sporadic acute or fulminant hepatitis E in Hokkaido, Japan, may be food-borne, as suggested by the presence of hepatitis E virus in pig liver as food.

Authors:  Yasuyuki Yazaki; Hitoshi Mizuo; Masaharu Takahashi; Tsutomu Nishizawa; Nobuhiko Sasaki; Yuhko Gotanda; Hiroaki Okamoto
Journal:  J Gen Virol       Date:  2003-09       Impact factor: 3.891

4.  Prevalence of Hepatitis E virus-specific antibodies in sera of German domestic pigs estimated by using different assays.

Authors:  Christine Baechlein; Anika Schielke; Reimar Johne; Rainer G Ulrich; Wolfgang Baumgaertner; Beatrice Grummer
Journal:  Vet Microbiol       Date:  2009-12-16       Impact factor: 3.293

5.  Hepatitis E virus infection in acute non-traumatic neuropathy: A large prospective case-control study in China.

Authors:  Yijin Wang; Shan Wang; Jian Wu; Yiyun Jiang; Haiying Zhang; Shujuan Li; Hongyang Liu; Changshuang Yang; Haijun Tang; Naizhou Guo; Maikel P Peppelenbosch; Lai Wei; Qiuwei Pan; Jingmin Zhao
Journal:  EBioMedicine       Date:  2018-09-03       Impact factor: 8.143

6.  Presence and persistence of hepatitis E virus RNA and proteins in human bone marrow.

Authors:  Lin Wang; Li Yan; Jieling Jiang; Yuyi Zhang; Qiyu He; Hui Zhuang; Ling Wang
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

7.  A Nationwide Survey of Hepatitis E Virus Infection and Chronic Hepatitis in Heart and Kidney Transplant Recipients in Japan.

Authors:  Yohei Owada; Yukio Oshiro; Yuki Inagaki; Hiroshi Harada; Nobuhiro Fujiyama; Naoki Kawagishi; Takashi Yagisawa; Joichi Usui; Naotake Akutsu; Yoshihiro Itabashi; Kazuhide Saito; Yoshihiko Watarai; Naotsugu Ichimaru; Ryoichi Imamura; Miyaji Kyakuno; Kentaro Ide; Yuichi Shibuya; Yasuhiro Okabe; Minoru Ono; Konosuke Sasaki; Akira Shiose; Kazumasa Yamagishi; Hiroshi Ohnishi; Shigeo Nagashima; Masaharu Takahashi; Kenji Yuzawa; Hiroaki Okamoto; Nobuhiro Ohkohchi
Journal:  Transplantation       Date:  2020-02       Impact factor: 5.385

8.  Foodborne Zoonoses Common in Hunted Wild Boars.

Authors:  Maria Fredriksson-Ahomaa; Laura London; Teresa Skrzypczak; Tuija Kantala; Ilona Laamanen; Mia Biström; Leena Maunula; Tuija Gadd
Journal:  Ecohealth       Date:  2020-12-16       Impact factor: 3.184

9.  Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults.

Authors:  Jiaye Liu; Ibrahim Ayada; Xiaofang Zhang; Ling Wang; Yang Li; Tianfu Wen; Zhongren Ma; Marco J Bruno; Robert J de Knegt; Wanlu Cao; Maikel P Peppelenbosch; Mohsen Ghanbari; Zhihui Li; Qiuwei Pan
Journal:  Clin Gastroenterol Hepatol       Date:  2021-02-20       Impact factor: 11.382

10.  Analyses of Clinical and Biological Data for French and Belgian Immunocompetent Patients Infected With Hepatitis E Virus Genotypes 4 and 3.

Authors:  Florence Micas; Vanessa Suin; Jean-Marie Péron; Caroline Scholtes; Edouard Tuaillon; Thomas Vanwolleghem; Laurence Bocket; Sébastien Lhomme; Chloé Dimeglio; Jacques Izopet; Florence Abravanel
Journal:  Front Microbiol       Date:  2021-04-14       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.